UCB shares fall 8.3% as FDA rejects Vimpat for DNP

Shares in UCB dropped 8.3% to to 21.44 euros on July 30, after the Belgian drugmaker received a "not-approvable" letter from the US Food and Drug Administration for Vimpat (lacosamide) for the treatment of diabetic neuropathic pain in adults. The company will seek clarification from the FDA of its position and of the additional information required to obtain final marketing approval. UCB confirmed that Vimpat is also currently under active review by the FDA for the adjunctive treatment of partial-onset seizures in patients with epilepsy, aged 16 and over.